A Diabetes-Atrial Fibrillation Conundrum Does Duration Trump Glycemia? ∗

The disease and cost burden of atrial fibrillation (AF) is expected to double over the next 25 years (1). With availability of newer therapies, efforts to refine the triage of who receives therapies, when, and for how long have assumed center stage. Over the last few years, a host of new scores such as CHADS-VASc (congestive heart failure [or Left ventricular systolic dysfunction], hypertension, age≥75 years, diabetes, prior Stroke, TIA, or thromboembolism, vascular disease [e.g. peripheral artery disease, myocardial infarction, aortic plaque], age 65–74 years, sex category) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) have emerged on the scene where the age-old CHADS score had reigned supreme (2–4).
Source: Journal of the American College of Cardiology - Category: Cardiology Source Type: research